Compass Pathways stock (GB00BKLLQZ68): FDA rolling review and fresh Q1 2026 data put psilocybin program in focus

Compass Pathways has reported first-quarter 2026 results and highlighted key regulatory milestones for its COMP360 psilocybin program, including FDA acceptance of a rolling NDA submission for treatment-resistant depression, drawing attention from US biotech investors.

Compass Pathways stock is back in focus after the mental health biotechnology company reported its first-quarter 2026 results and business highlights and announced that the US Food and Drug Administration (FDA) has granted a rolling submission and review for its planned new drug application (NDA) for COMP360 in treatment-resistant depression (TRD), according to a company press release published on May 13, 2026 on Business Wire and the Compass investor relations site Compass Pathways Q1 2026 release as of 05/13/2026.

Management also flagged upcoming catalysts, including 26-week data from a key study expected in early third quarter 2026 and ongoing regulatory interactions in both the US and UK, while an analyst note from TD Cowen maintained a Buy rating on the stock following progress on the NDA process, according to a May 2026 report summarized by Investing.com as of 05/14/2026.

As of: 05/14/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Compass Pathways plc
• Sector/industry: Biotechnology / mental health therapeutics
• Headquarters/country: London, United Kingdom
• Core markets: United States and Europe, with a focus on psychiatric indications
• Key revenue drivers: Potential future sales of COMP360 for treatment-resistant depression and other mental health conditions, if approved
• Home exchange/listing venue: Nasdaq Global Select Market (ticker: CMPS)
• Trading currency: US dollar (USD)

Compass Pathways: core business model

Compass Pathways operates as a clinical-stage biotechnology company focused on developing psychedelic-based therapies for serious mental health conditions where existing treatment options are limited. Its lead investigational product, COMP360, is a proprietary formulation of synthetic psilocybin that has been studied alongside psychological support in company-sponsored clinical trials for treatment-resistant depression and other potential indications, as described in corporate materials and press releases such as the Q1 2026 update Compass Pathways Q1 2026 release as of 05/13/2026.

The company describes its mission as accelerating patient access to evidence-based innovation in mental health, particularly for populations who do not respond adequately to current standards of care. In practice, this means designing and executing late-stage clinical trials, securing regulatory designations such as breakthrough or expedited pathways where applicable, and planning for potential commercialization of COMP360 in partnership with health systems if the therapy gains approval in major markets including the US and UK, according to company statements in recent regulatory filings and news updates cited in the first-quarter 2026 announcement Compass Pathways Q1 2026 release as of 05/13/2026.

Compass Pathways’ business model remains pre-revenue and research-intensive, with operating expenses driven largely by clinical development, regulatory work, and the build-out of therapy support infrastructure for COMP360 sessions. The company’s strategic focus is to establish COMP360 as a differentiated, possibly rapid-acting treatment option in TRD and explore additional psychiatric indications, which in turn could support future licensing, reimbursement agreements, and potential commercial roll-out in the US market, where many institutional and retail investors track the Nasdaq-listed stock.

Main revenue and product drivers for Compass Pathways

As of the first quarter of 2026, Compass Pathways’ primary value driver is the clinical and regulatory progress of COMP360 for treatment-resistant depression, a condition characterized by inadequate response to multiple prior antidepressant treatments. The company recently completed key Phase 3 studies and is preparing an NDA submission to the FDA for COMP360 in TRD, with the agency having granted a rolling submission and review process based on the strength of the Phase 3 data, according to the company’s May 13, 2026 press release summarizing first-quarter results and regulatory milestones Compass Pathways Q1 2026 release as of 05/13/2026.

In the same update, Compass highlighted that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted COMP360 an Innovative Licensing and Access Pathway (ILAP) designation for TRD, a framework intended to accelerate time to market for promising therapies. This ILAP status in the UK, combined with the FDA’s rolling NDA review in the US, underscores the regulatory momentum behind COMP360 and supports the company’s view that it could assemble a robust clinical package by the fourth quarter of 2026 with the aim of securing approval, as stated by Chief Executive Officer Kabir Nath in the first-quarter 2026 release Compass Pathways Q1 2026 release as of 05/13/2026.

Beyond TRD, Compass is evaluating COMP360 in other indications, including post-traumatic stress disorder and potentially additional mood or anxiety-related conditions, though these programs are generally at an earlier stage relative to the TRD franchise. The company has also invested in therapist training and integration of support protocols, recognizing that COMP360 therapy is delivered in conjunction with psychological support, which could become an important component of how payers, regulators, and treatment centers view the overall value proposition of the product once it reaches the commercial phase.

Financially, Compass remains loss-making as it invests in clinical development. According to a May 14, 2026 summary of the first-quarter 2026 figures, Compass reported a net loss of around $91.2 million for the period and earnings per share of negative $0.71, while ending the quarter with approximately $466 million in cash resources, which is expected to fund operations through key regulatory milestones, as reported by Investing.com as of 05/14/2026. These figures frame the company’s capacity to finance its NDA submission activities and preparations for potential commercialization in the US and other markets if approvals are granted.

Why Compass Pathways matters for US investors

For US investors, Compass Pathways offers exposure to the emerging field of psychedelic-assisted therapies, a niche but rapidly developing segment within biotechnology. The company’s Nasdaq listing under the ticker CMPS provides straightforward access for US-based retail and institutional investors who track mental health innovation and high-risk, high-reward biotech stories. With the US representing one of the largest markets for depression treatment, any potential approval of COMP360 in TRD could be especially relevant for domestic healthcare spending and reimbursement discussions, as suggested by the company’s focus on the US in its regulatory strategy outlined in the first-quarter 2026 business highlights Compass Pathways Q1 2026 release as of 05/13/2026.

US investors also pay attention to regulatory designations such as the FDA’s rolling NDA review and prior breakthrough therapy status because these can influence timelines, perceived probability of approval, and ultimately potential market penetration if COMP360 reaches the commercial stage. The combination of a substantial addressable patient population in treatment-resistant depression and the unique mechanism of action of psilocybin-based therapy has led several Wall Street firms to follow the stock closely, with TD Cowen, for example, maintaining a Buy rating in mid-May 2026 following progress on the NDA process, according to Investing.com as of 05/14/2026.

However, US investors must also consider the regulatory and societal complexities associated with psychedelic substances, which remain controlled under federal law in many contexts. Even if COMP360 is approved, its use will likely be tightly regulated and may require specialized treatment centers and trained therapists, factors that could shape adoption curves as well as reimbursement. As a result, the trajectory of Compass Pathways’ stock may remain closely tied to news on regulatory decisions, payer discussions, and the company’s ability to build a scalable treatment ecosystem in the US healthcare market.

Conclusion

Compass Pathways has entered a pivotal phase in 2026, with the FDA’s acceptance of a rolling NDA submission for COMP360 in treatment-resistant depression and the UK’s ILAP designation underscoring regulatory interest in its psilocybin-based therapy. First-quarter 2026 results highlight that the company remains a pre-revenue, loss-making biotech but with a cash position that, according to recent disclosures, should support progress through several upcoming milestones. For US investors following the Nasdaq-listed stock, the story now centers on regulatory timelines, forthcoming clinical readouts such as the 26-week data expected in early third quarter 2026, and the practical challenges of integrating psychedelic-assisted therapy into existing healthcare systems. The balance between high unmet medical need in mental health and the execution risks around approval, reimbursement, and adoption will likely continue to shape sentiment around Compass Pathways in the months ahead.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.